394 related articles for article (PubMed ID: 30229376)
21. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
22. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
23. Diffusion and use of health technology assessment in policy making: what lessons for decentralised healthcare systems?
Ciani O; Tarricone R; Torbica A
Health Policy; 2012 Dec; 108(2-3):194-202. PubMed ID: 23093020
[TBL] [Abstract][Full Text] [Related]
24. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
25. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
26. Health technology assessment in Brazil - an international perspective.
Lima SGG; Brito C; Andrade CJC
Cien Saude Colet; 2019 May; 24(5):1709-1722. PubMed ID: 31166506
[TBL] [Abstract][Full Text] [Related]
27. The HTA Core Model
Kristensen FB; Lampe K; Wild C; Cerbo M; Goettsch W; Becla L
Value Health; 2017 Feb; 20(2):244-250. PubMed ID: 28237203
[TBL] [Abstract][Full Text] [Related]
28. Healthcare Databases in Thailand and Japan: Potential Sources for Health Technology Assessment Research.
Saokaew S; Sugimoto T; Kamae I; Pratoomsoot C; Chaiyakunapruk N
PLoS One; 2015; 10(11):e0141993. PubMed ID: 26560127
[TBL] [Abstract][Full Text] [Related]
29. A Conceptual Framework for Life-Cycle Health Technology Assessment.
Kirwin E; Round J; Bond K; McCabe C
Value Health; 2022 Jul; 25(7):1116-1123. PubMed ID: 35779939
[TBL] [Abstract][Full Text] [Related]
30. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
[TBL] [Abstract][Full Text] [Related]
31. Advanced therapy medicinal products: current and future perspectives.
Hanna E; Rémuzat C; Auquier P; Toumi M
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy: evidence, value and affordability in the US health care system.
Hampson G; Towse A; Pearson SD; Dreitlein WB; Henshall C
J Comp Eff Res; 2018 Jan; 7(1):15-28. PubMed ID: 29144165
[TBL] [Abstract][Full Text] [Related]
33. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
34. Health technology assessment and primary data collection for reducing uncertainty in decision making.
Goeree R; Levin L; Chandra K; Bowen JM; Blackhouse G; Tarride JE; Burke N; Bischof M; Xie F; O'Reilly D
J Am Coll Radiol; 2009 May; 6(5):332-42. PubMed ID: 19394574
[TBL] [Abstract][Full Text] [Related]
35. Surgery Versus ATMPs: An Example From Ophthalmology.
Magrelli FM; Merra A; Pellegrini G
Front Bioeng Biotechnol; 2020; 8():440. PubMed ID: 32587848
[TBL] [Abstract][Full Text] [Related]
36. HEALTH TECHNOLOGY ASSESSMENT IN TURKEY.
Kahveci R; Koç EM; Küçük EÖ
Int J Technol Assess Health Care; 2017 Jan; 33(3):402-408. PubMed ID: 28595660
[TBL] [Abstract][Full Text] [Related]
37. Health technology assessment: research trends and future priorities in Europe.
Nielsen CP; Funch TM; Kristensen FB
J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
[TBL] [Abstract][Full Text] [Related]
38. CAT--the new committee for advanced therapies at the European Medicines Agency.
Celis P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354
[TBL] [Abstract][Full Text] [Related]
39. GUIDING PRINCIPLES FOR GOOD PRACTICES IN HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT UNITS.
Sampietro-Colom L; Lach K; Pasternack I; Wasserfallen JB; Cicchetti A; Marchetti M; Kidholm K; Arentz-Hansen H; Rosenmöller M; Wild C; Kahveci R; Ulst M
Int J Technol Assess Health Care; 2015; 31(6):457-65. PubMed ID: 26899230
[TBL] [Abstract][Full Text] [Related]
40. Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective.
Xie F; Bowen JM; Sutherland SC; Burke N; Blackhouse G; Tarride JE; O'Reilly D; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):513-21. PubMed ID: 21958096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
